Referencias:

• Fleisch, H., (1995) Bisphosphonates in Bone Disease. From the Laboratory to the Patient, , The Partenon Publishing group, London
• Weideman, M., Toxicity tests in animals: Historical perspectives and new opportunities (1993) Environ Health Perspect, 101, pp. 222-225
• Roldán, E.J.A., Mondelo, N., Piccinni, E., Peluffo, V.A., Montuori, E., Olpadronic acid sodium salt. Treatment for Paget's Bone Disease. Treatment for Osteoporosis (1995) Drugs Fut, 20, pp. 1123-1127
• Lin, J.H., Bisphosphonates: A review of their pharmacokinetic properties (1996) Bone, 18, pp. 75-85
• Mautalen, C.A., Casco, C.A., Gonzalez, D., Ghiringhelli, G.R., Massironi, C., Fromm, G.A., Plantalech, L., Side effects of disodium aminohydroxypropylidene diphosphonate (APD) during treatment of bone diseases (1984) BMJ, 288, pp. 828-829
• Spivacow, F., Zanchetta, J.R., Kerzberg, E., Frigeri, A., Fiasché, R., Roldán, E.J.A., Tolerability of oral pamidronate in elderly patients with osteoporosis and other metabolic bone diseases (1996) Curr Ther Res, 57, pp. 123-130
• Peter, C.P., Guy, J., Shea, M., Bagdon, W., Kline, W.F., Hayes, W., Long-term safety of the aminobisphosphonate Alendronate in adult dogs. I. General safety and biomechanical properties of bone J Pharm Exp Ther, 276, pp. 271-276
• Cal, J.C., Cokshott, A., Daley Yates, P.T., Experimental acute renal failure induced by 3 - Amino-1-hydroxypropylidene-1,1-bisphosphonate in rodents (1991) Nephrotoxicity, pp. 43-48. , Bach P.H., Ed. Dekker, New York
• Roldán, E.J.A., Kerzberg, E.M., Castelli, G., Pérez Lloret, A., Efecto de bajas dosis del pamidronate (APD) oral sobre la calcemia de pacientes osteopénicas u osteoporóticas (1996) Medicina (Buenos Aires), 56, pp. 133-137
• Francis, M., Slough, C., Acute intravenous infusion of disodium dihydrogen (1- Hydroxyethylidene) disphosphonate: Mechanism of toxicity (1984) J Pharm Sci, 73, pp. 1097-1100
• Schenk, R., Merz, W.A., Muhlbauer, R., Russell, R.G.G., Fleisch, H., Effect of ethane-1-hydroxy- 1,1-disphosphonate (EHDP) and dichloromethyl-anedisphosphonate (CI 2MDP) on the calcification and resorption of cartilage and bone in the tibial epiphysis and metaphysis of rats (1973) Calcif Tissue Int, 11, pp. 196-214
• Boyce, B.F., Smith, L., Fogelman, I., Johnston, E., Ralston, S., Boyle, I.T., Focal osteomalacia due to low dose diphosphonate therapy in Paget's disease (1984) Lancet, 1, pp. 821-824
• Mondelo, N., Peluffo, V.A., Zanchetta, J.R., Preclinical pharmacology of Olpadronate, a new dimethylated aminobisphosphonate (1996) Proc VI World Conference on Clinical Pharmacology and Therapeutics, , Buenos Aires, Agosto de
• Cointry, G.R., Mondelo, N., Zanchetta, J.R., Montuori, E., Ferretti, J.L., Olpadronate restores ovariectomy-affected bone strength A mechanical, densitometric and tomographic (pQCT) study (1995) Bone, 17 (SUPPL.), pp. S373-S378
• Ferretti, J.L., Mondelo, N., Capozza, R.F., Cointry, G.R., Zanchetta, J.R., Montuori, E., Effects of large doses of Olpadronate (dimethyl-pamidronate) on mineral density, cross-sectional architecture and mechanical properties of rats femurs (1995) Bone, 17 (SUPPL.), pp. 285S-93S
• Mondelo, N., Montuori, E., Peluffo, V.A., Capozza, R.F., Cointry, G.R., Morillo, S., Zanchetta, J.R., Ferretti, J.L., Sub-chronic effects of high doses of Mildronate (Olpadronate) on femur densitometric (DEXA), tomographic (pQCT) and mechanical properties in young rats (1994) Bone Miner, 25 (1 SUPPL.), pp. S61
• Ferretti, J.L., Ma, Y.F., Jerome, C., Cointry, G.R., Capozza, R.F., Mondelo, N., Montuori, E., Jee, S.S., Efectos subcrónicos del Olpadronato (Dimetil-pamidronato, Me 2APD) sobre el fémur de rata in vivo II. Cambios metafisarios tomográficos (Resumen) (1994) Actas de la XI Reunión Anual de la Asociación Argentina de Osteología y Metabolismo Mineral, , Buenos Aires, Noviembre de
• Cointry, G.R., Mondelo, N., Peluffo, V., Montuori, E., Zanchetta, J.R., Ferretti, J.L., Femur mass, architecture, mineralization and strength as affected by high doses of Olpadronate in mice. A tomographic (pQCT) and biomechanical study (1996) J Bone Miner Res, 11 (1 SUPPL.), pp. 337S
• Guy, J.A., Shea, M., Peter, C.P., Morrissey, R., Hayes, W.C., Continuous Alendronate treatment throughout growth, maturation and aging in the rat results in increases in bone mass and mechanical properties (1993) Calcif Tissue Int, 53, pp. 283-288
• Fratzl, P., Schreiber, S., Roschger, P., Lafage, M.-H., Rodan, G., Klaushofer, K., Effects of sodium fluoride and Alendronate on the bone mineral in minipigs : A small-angle X-ray scattering and backscattered electron imaging study (1996) J Bone Miner Res, 11, pp. 248-253
• Ferretti, J.L., Cointry, G., Capozza, R., Montuori, E., Roldán, E., Pérez Lloret, A., Biomechanical effects of the full range of useful doses of (3-amino-1-hydroxypropylidene)-1,1- Bisphosphonate (APD) on femur diaphyses and cortical bone tissue in rats (1990) Bone Miner, 11, pp. 111-122
• Grynpas, M.D., Acito, A., Dumitriu, M., Mertz, B.P., Very, J.M., Changes in bone mineralization, architecture and mechanical properties due to long-term (1 year) administration of APD to dogs (1992) Osteoporosis Int, 2, pp. 74-81
• Grynpas, M.D., Kasra, M., Dumitriu, M., Nespeca, R., Very, J.M., Mertz, B.P., Recovery from pamidronate (APD): A two-year study in the dog (1994) Calcif Tissue Int, 55, pp. 288-294
• Weile, V., Josephsen, K., Fejerskov, O., Scanning electron microscopy fo final enamel formation in rat mandibular incisors following single injections of 1-hydroxyethylidene -1,1- Bisphosphonate (1993) Calcif Tissue Int, 52, pp. 318-324

Citas:

---------- APA ----------

---------- CHICAGO ----------

---------- MLA ----------

---------- VANCOUVER ----------